C9171 Injection, pegulicianine Reimbursement

HCPCS Level II code C9171 identifies the injectable drug pegulicianine, billed per 1 mg. Pegulicianine is billed as a discrete drug product unit and is relevant for settings that administer specialized injectable agents, including outpatient infusion clinics, ambulatory surgical centers, and physician offices. Nationally, accurate reporting of drug-specific HCPCS codes matters for drug utilization tracking, reimbursement consistency, and formulary management across public and private payers.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what C9171 represents, typical sites of service, and the common payer landscape. The publication provides benchmarks for utilization and payment where available, summarizes notable policy or coding updates affecting HCPCS drug coding, and outlines clinical context around use of injectable agents billed per milligram. Where input data are missing, statements note that specific details are not available.

This summary is intended for billing managers, revenue cycle professionals, and policy analysts seeking a national perspective on HCPCS drug coding, reimbursement implications, and operational considerations for documenting and billing pegulicianine.

Billing Code Overview

HCPCS Level II code C9171 describes Injection, pegulicianine, 1 mg. This code covers administration of the active drug product measured per milligram and is used to report the billed item for the pharmaceutical agent pegulicianine.

Service type: Therapeutic or diagnostic injectable medication administration associated with a single-dose drug product
Typical site of service: Outpatient infusion clinic, ambulatory surgical center, physician office, or other settings where injectable drugs are administered

Data not available in the input.

Clinical Context

A typical patient is an adult with visual impairment due to a small, focal, residual choroidal neovascular membrane or persistent subretinal neovascularization after prior therapies. The patient presents to an outpatient ophthalmology specialty clinic for intravitreal pharmacologic therapy using C9171 (injection, pegulicianine, 1 mg). The clinical workflow includes pre-procedure evaluation with visual acuity, intraocular pressure check, slit-lamp and dilated fundus examination, imaging such as optical coherence tomography (OCT) and fluorescein angiography as indicated, informed consent documenting risks and benefits, medication preparation under aseptic technique, peri‑procedural topical anesthesia and povidone-iodine antisepsis, administration of the intravitreal injection, post-injection pressure and corneal checks, and written aftercare instructions with follow-up scheduling for outcome assessment and monitoring for endophthalmitis or increased intraocular pressure. Billing uses HCPCS Level II code C9171 for the drug product per 1 mg unit; the encounter may include separate billing for facility or professional services and any associated procedural CPT codes for intravitreal injection if applicable.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased Procedural Services	Use when work required to administer is substantially greater than typically required (unusual complexity documented).

Taxonomy Code	Specialty	Notes
`162W00000X`	Ophthalmology	Retina specialists and comprehensive ophthalmologists perform intravitreal injections.
`207RC0000X`	Ophthalmic Surgery	Subspecialists focusing on surgical retinal procedures commonly administer intravitreal therapeutics.
`103T00000X`	Emergency Medicine	May administer intravitreal antibiotics or manage acute complications emergently, less commonly for `C9171`.
`2080S0002X`	Optometry	Therapeutic optometrists may be involved in pre- and post-injection care in some jurisdictions, not typically administering this intravitreal agent.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`H35.32`	Exudative age-related macular degeneration	Common indication for intravitreal pharmacologic agents targeting subretinal neovascularization treated with `C9171` in selected cases.
`H35.35`	Myopic degeneration with choroidal neovascularization	Pathology that can produce choroidal neovascular membranes addressed by intravitreal biologics like `C9171`.
`H35.81`	Retinal neovascularization	Reflects proliferative neovascular processes that may be assessed and managed with intravitreal agents.
`H31.033`	Serous detachment of macula, bilateral	Macular fluid and detachment associated with neovascular disease where intravitreal therapy may be indicated.
`H44.1`	Endophthalmitis	Important to document as a complication; relevant to post-injection monitoring and urgent management planning.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`67028`	Intravitreal injection of a pharmacologic agent (separate procedure)	Commonly billed for the intravitreal administration procedure when a physician performs the injection of `C9171`.
`92083`	Diagnostic imaging, OCT with interpretation and report, unilateral	Often performed before or after injection to document retinal anatomy and response to `C9171` therapy.
`92225`	Fluorescein angiography with interpretation and report (intravenous)	Used to characterize neovascular membranes and guide use of `C9171` when vascular leakage evaluation is needed.
`99213`	Office visit for established patient, low to moderate complexity	Typical outpatient evaluation visit code associated with pre- or post-injection assessment when evaluation and management services are billed.
`99070`	Supplies and materials (eg, drugs requiring specific handling), additional	May be used per payer guidance for non-covered supply costs related to drug preparation or special disposables when applicable.

OpenPayer

Summary & Overview

HCPCS C9171: Injection, pegulicianine, 1 mg